Why Should You Consider EPAT?
Are you tired of being in pain?
Patients, like you, who suffer from acute and chronic musculoskeletal pain now have access to an innovative,
non-invasive treatment that will get you feeling better, faster.
CuraMedix Extracorporeal Pulse Activation Technology (EPAT) is the most advanced non-invasive technology which uses energy based on unique sets of acoustic pressure waves.
EPAT helps to improve the regenerative potential, rather than further damage an area that has degenerated because of poor blood flow, tissue injury, overuse or weakness.
In as few as three weekly five to ten minute sessions, you’ll be able to return to your favorite sport or activity. And there’s no downtime.
What is EPAT?
Extracorporeal Pulse Activation Technology (EPAT), sometimes referred to as ESWT or shock wave therapy, is the most advanced and highly effective non-invasive treatment method cleared by the FDA. This proprietary technology is based on a unique set of pressure waves that stimulate the metabolism, enhance blood circulation and accelerate the healing process.
What disorders can be treated?
Generally, acute or chronic musculoskeletal pain and/or pain that significantly impairs mobility or quality of life including:
• Foot and heel pain
• Achilles pain
• Tendon and/or tendon insertion pain
• Trigger points
What are the expected results?
Some patients report immediate pain relief after the treatment, although it can take up to four weeks for pain relief to begin. The procedure eliminates pain and restores full mobility, thus improving your quality of life. Over 80% of patients treated report to be pain free and/or have significant pain reduction.
Is it safe?
Yes. This FDA cleared technology was developed in Europe and is currently used around the globe. A wealth of medical experience, state-of-the-art engineering and optimal quality have been built into each EPAT device, and extensive clinical studies and tests have confirmed its safety and efficacy.
Stay tuned for more information about EPAT!Read the rest of this entry.